A Randomized Phase 2 Study of LY2181308 in Combination With Docetaxel Versus Docetaxel in Hormone Refractory Prostate Cancer

Inclusion Criteria:

- Histologically or cytologically confirmed adenocarcinoma of the prostate which is
metastatic and/or unresectable

- Hormone refractory prostate cancer defined as progressive based by documented 2
increase PSA values over a previous reference value.

- ECOG status 0-2

- Adequate hematological functions, liver and renal functions

Exclusion Criteria:

- Known hypersensitivity to docetaxel or taxane therapy

- Documented central nervous system or leptomeningeal metastasis at time of study entry

- Had prior treatment with chemotherapy, bone seeking radionucleides in past 6 weeks
prior to enrollment, or radiotherapy involving more than 25% of marrow producing
area.

- Evidence of painful and/or destructive bone metastases for which radiation therapy,
biophosphonates or boneseeking radionucleides are necessary.

- Have received treatment in the last 30 day with a drug which has not received
regulatory approval for any indication at the time of study entry.